Proteonomix, Inc. (PROT) Announces That Its Subsidiary, Proteoderm, Inc., Has Entered Into a Letter of Intent With Sinoquest Investment Limited for the Licensing, Purchase and Distribution of Proteoderm’s Cosmoceutical Containing Its Patent-Pending Bioact

MOUNTAINSIDE, NJ--(Marketwire - December 15, 2008) - Proteonomix, Inc. (PINKSHEETS: PROT) announces that its wholly-owned subsidiary, Proteoderm, Inc., and Sinoquest Investment Limited have signed a letter of intent (LOI), whereby, under a definitive agreement to be consummated, Sinoquest will gain exclusive rights in China, Taiwan, and Hong Kong to purchase for distribution of Proteoderm's revolutionary new stem cell-derived skin care products containing the bioactive protein matrix NC-138™. The products include Proteoderm's special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a license of its name and the right to use the material in Sinoquest's own containers. Both companies expect to begin distribution in the first quarter of 2009.
MORE ON THIS TOPIC